Tag: bevacizumab biosimilars market share

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Bevacizumab Biosimilars Market Size Forecast: How Big Could The Market Get By 2030?

The bevacizumab biosimilars market size has demonstrated significant expansion in recent years. This market is set to increase from $1.64 billion in 2025 to $1.77 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. Historically, this growth can be attributed to several factors, including the patent expiry of reference bevacizumab, the rising prevalence of cancer, a growing demand for cost-effective biologics, government incentives supporting biosimilars, and advancements in recombinant DNA technology.

The bevacizumab biosimilars market is poised for significant expansion in the coming years. Its valuation is projected to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. This expansion during the forecast period is driven by factors such as a rise in biosimilar approvals, the penetration into developing markets, the incorporation of AI into drug discovery, a heightened demand for outpatient oncology services, and strategic alliances among pharmaceutical entities. Key developments anticipated during the forecast span involve a greater uptake of biosimilars in cancer treatment, the availability of more economical therapeutic options, an increase in regulatory clearances for biosimilars, the broadening of hospital and retail pharmacy infrastructures, and the proliferation of specialized cancer treatment facilities.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Bevacizumab Biosimilars Market Growth Drivers: What’s Behind The Acceleration?

An increasing occurrence of cancer cases is projected to boost the expansion of the bevacizumab biosimilar market in the future. Cancer incidence quantifies the new cancer cases observed within a particular population over a specified timeframe. Bevacizumab, a biologic, works by inhibiting tumor angiogenesis, thereby facilitating tumor shrinkage and hindering growth, demonstrating similar efficacy and safety to reference biologics for patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For example, the NHS England, a UK-based government department, reported in October 2025 that England saw 354,820 new cancer diagnoses in 2023, marking an increase of 8,605 from 2022. Consequently, the growing prevalence of cancer cases fuels the bevacizumab biosimilars market.

Bevacizumab Biosimilars Market Segment Landscape: Which Areas Lead Development?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Bevacizumab Biosimilars Market Trends: What’s Defining The Industry’s Next Phase?

Major companies in the bevacizumab biosimilars market are prioritizing technological advancements, such as next-generation indication-expanded formulations, to address the growing need for more adaptable and cost-effective biologic therapies across both oncology and non-oncology indications. These sophisticated formulations modify the core bevacizumab antibody for novel administration methods or new indications, allowing for non-oncologic applications (e.g., ophthalmology) or more patient-compliant dosing, all while maintaining the identical VEGF-neutralizing mechanism utilized by traditional intravenous bevacizumab. For example, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical firm, introduced Versavo (bevacizumab) in the UK. This high-quality biosimilar of Avastin (bevacizumab) is produced for oncology applications, making treatments for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more accessible for a wider patient population. Versavo is provided in 100 mg and 400 mg single-use vials, consistent with standard bevacizumab dosages, and offers a biosimilar cost benefit that helps reduce the financial strain on healthcare systems and individuals relying on anti-VEGF therapy.

Bevacizumab Biosimilars Market Industry Leaders And Competitive Landscape

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

View The Full Bevacizumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Bevacizumab Biosimilars Market Regional Analysis And Leading Geography

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Bevacizumab Biosimilars Market Revenue Growth Supported By A CAGR Of 2.42% Through 2030

The bevacizumab biosimilars market has experienced notable expansion in recent years, with projections showing an increase from $1.64 billion in 2025 to $1.77 billion in 2026, representing a compound annual growth rate (CAGR) of 7.5%. This historical growth has been driven by factors such as the expiration of patents on reference bevacizumab, a growing incidence of cancer, a higher demand for affordable biologic treatments, government support promoting biosimilar adoption, and progress in recombinant DNA technology.

The bevacizumab biosimilars market is projected to experience robust expansion over the coming years, reaching a valuation of $2.42 billion by 2030 with a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is driven by several key factors, including a rising number of biosimilar approvals, the expansion of markets in developing regions, the integration of artificial intelligence into drug development processes, a growing preference for outpatient oncology care, and increased strategic alliances among pharmaceutical companies. Key trends shaping this period include the broader uptake of biosimilars within oncology, the availability of cost-effective treatment options, an increase in regulatory clearances for biosimilars, the widening reach of hospital and retail pharmacy networks, and the emergence of more specialized cancer treatment centers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Bevacizumab Biosimilars Market Development Factors: Which Trends Are Supporting Demand?

The anticipated expansion of the bevacizumab biosimilar market is being driven by the growing number of cancer cases. Cancer incidence describes the count of newly diagnosed cancer cases within a defined population over a specified timeframe. Bevacizumab, a biologic agent, works by blocking tumor angiogenesis, resulting in tumor reduction and halted growth, and it demonstrates comparable effectiveness and safety to original biologics when used for patients with advanced non-small cell lung cancer or metastatic colorectal cancer. As an example, data from NHS England, a UK governmental body, revealed in October 2025 that 354,820 new cancer diagnoses were recorded in England during 2023—an increase of 8,605 from the previous year. Consequently, the upward trend in cancer prevalence is fueling demand for bevacizumab biosimilars.

Bevacizumab Biosimilars Market Segment Outlook: Which Categories Are Expanding The Fastest?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Bevacizumab Biosimilars Market Transformation Trends: Which Innovations Are Driving Change?

Leading players in the bevacizumab biosimilars market are driving innovation with next-generation formulations designed for expanded indications, aimed at satisfying the growing need for more flexible and economical biologic treatments in both oncology and non-oncology fields. These enhanced formulations adapt the core bevacizumab antibody for alternative delivery methods or uses beyond cancer, such as ophthalmology, or for easier patient dosing schedules, all while preserving the VEGF-neutralizing mechanism seen in conventional intravenous bevacizumab. A notable example occurred in March 2024, when Dr. Reddy’s Laboratories, a pharmaceutical firm based in India, introduced Versavo (bevacizumab) in the UK as a high-quality biosimilar to Avastin, specifically developed for oncology purposes, thereby making treatments for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more accessible to a broader patient population. Supplied in 100 mg and 400 mg single-use vials, Versavo aligns with standard bevacizumab dosing regimens while offering a cost-effective biosimilar alternative that eases the financial strain on healthcare systems and patients relying on anti-VEGF therapy.

Bevacizumab Biosimilars Market Key Companies And Competitive Benchmarking

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Access The Complete Bevacizumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Bevacizumab Biosimilars Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Bevacizumab Biosimilars Market During 2026–2030?

The bevacizumab biosimilars market size has experienced robust expansion in recent years. This market is projected to expand from $1.64 billion in 2025 to $1.77 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.5%. Historically, factors such as the patent expiration of reference bevacizumab, an increase in cancer prevalence, the need for economical biologics, governmental support for biosimilars, and progress in recombinant DNA technology have driven this growth.

The bevacizumab biosimilars market size is projected to undergo significant expansion in the coming years, reaching a value of $2.42 billion by 2030, with a compound annual growth rate (CAGR) of 8.2%. This anticipated increase is attributed to a rise in biosimilar approvals, the expansion into developing markets, the integration of AI into drug development processes, a growing inclination towards outpatient oncology care, and strategic collaborations among pharmaceutical firms. Key trends for the forecast period include a greater embrace of biosimilars in oncology, the provision of cost-effective treatment alternatives, an increase in regulatory clearances for biosimilars, the broadening of hospital and retail pharmacy networks, and the proliferation of specialized cancer treatment centers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Influential Factors Are Boosting The Bevacizumab Biosimilars Market Demand?

The increasing occurrence of cancer cases is anticipated to drive expansion in the bevacizumab biosimilar market going forward. Cancer incidence quantifies the new cancer diagnoses within a defined population over a particular timeframe. Bevacizumab, a biologic, functions by blocking tumor angiogenesis, which can lead to reduced tumor size and inhibited growth, and it demonstrates comparable effectiveness and safety to reference biologics when treating individuals with advanced non-small cell lung cancer or metastatic colorectal cancer. As an illustration, in October 2025, according to the NHS England, a UK-based government department, there were 354,820 new cancer diagnoses in England in 2023, which represents an increase of 8,605 from 2022. Consequently, the growing frequency of cancer cases is fueling the bevacizumab biosimilars market.

How Are Different Segment Groups Identified Within The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Which Trends Are Shaping The Bevacizumab Biosimilars Market Landscape?

Major companies within the bevacizumab biosimilars market are concentrating on technological advancements, such as next-generation formulations with expanded indications, to address the growing need for more adaptable and affordable biologic therapies across both oncology and non-oncology applications. These sophisticated formulations adapt the fundamental bevacizumab antibody for new administration routes or indications, allowing for non-cancerous uses (for example, in ophthalmology) or more patient-friendly dosing, while still retaining the same VEGF-neutralizing mechanism employed by traditional intravenous bevacizumab. For instance, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, introduced Versavo (bevacizumab) in the UK. This high-quality biosimilar of Avastin (bevacizumab) is manufactured for oncology applications, thereby making treatments for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more financially attainable for a broader patient population. Versavo is supplied in 100 mg and 400 mg single-use vials, aligning with standard bevacizumab dosing, and offers a biosimilar cost-benefit that assists in reducing the financial burden on healthcare systems and patients reliant on anti-VEGF therapy.

Who Are The Firms Contributing To The Bevacizumab Biosimilars Market Ecosystem?

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Access The Complete Bevacizumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Contributes The Most To The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Bevacizumab Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Bevacizumab Biosimilars Market Expected To Reach Based On Its 2026 Value?

The bevacizumab biosimilars market size has experienced robust growth in recent years. It is anticipated to expand from $1.64 billion in 2025 to $1.77 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.5%. Historically, the growth in this market can be ascribed to elements such as the patent expiry of reference bevacizumab, an increase in cancer prevalence, the rising demand for cost-effective biologics, government incentives for biosimilars, and ongoing advancements in recombinant DNA technology.

The bevacizumab biosimilars market is projected to experience substantial expansion in the coming years, reaching a valuation of $2.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is primarily attributed to factors such as a rise in biosimilar approvals, the broadening of presence in emerging markets, the incorporation of AI into drug development processes, a growing inclination towards outpatient oncology treatment, and strategic alliances among pharmaceutical firms. Key trends anticipated during the same period encompass a heightened uptake of biosimilars in oncology, the availability of more economical treatment options, an increase in regulatory authorizations for biosimilar products, the expansion of both hospital and retail pharmacy infrastructures, and the proliferation of specialized cancer treatment facilities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Leading Drivers Are Supporting The Bevacizumab Biosimilars Market Expansion?

The increasing incidence of cancer cases is anticipated to fuel the expansion of the bevacizumab biosimilar market moving forward. Cancer incidence refers to the count of new cancer diagnoses observed in a specific demographic over a defined duration. Bevacizumab is a biologic agent that inhibits tumor angiogenesis, potentially leading to tumor shrinkage and suppressed growth, and it exhibits comparable effectiveness and safety to reference biologics when treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in October 2025, according to the NHS England, a UK-based government department, there were 354,820 new cancer diagnoses in England in 2023, which represents 8,605 more than in 2022. Therefore, the rising prevalence of cancer cases acts as a significant impetus for the bevacizumab biosimilars market.

What Segment Categories Shape The Bevacizumab Biosimilars Market Segment Landscape?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

What Trends Are Shaping The Future Of The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market are concentrating on technological progress, such as next-generation indication-expanded formulations, to address the increasing need for more adaptable and cost-effective biologic treatments across oncology and non-oncology indications. These advanced formulations allow the core bevacizumab antibody to be used in new ways or for new conditions, permitting non-oncologic applications (e.g., ophthalmology) or simpler patient dosing, all while retaining the same VEGF-neutralizing action that traditional intravenous bevacizumab uses. For instance, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, introduced Versavo (bevacizumab) in the UK. This product is a premium biosimilar of Avastin (bevacizumab) developed for oncology treatments, making therapies for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more affordable for a wider patient base. Versavo is supplied in 100 mg and 400 mg single-use vials, consistent with standard bevacizumab dosing, and provides a biosimilar cost advantage that helps lessen the financial strain on healthcare systems and patients who depend on anti-VEGF therapy.

Who Are The Companies Operating Across The Bevacizumab Biosimilars Market Value Chain?

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Get The Full Bevacizumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Accounts For The Largest Portion Of The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Bevacizumab Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Bevacizumab Biosimilars Market During The Forecast Period 2026–2030?

The bevacizumab biosimilars market size has experienced substantial expansion in recent times. This market is projected to expand from $1.64 billion in 2025 to $1.77 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. Historically, the market’s growth was driven by factors such as the patent expiry of reference bevacizumab, an increase in cancer prevalence, the rising demand for cost-effective biologics, government incentives for biosimilars, and progress in recombinant DNA technology.

The bevacizumab biosimilars market is projected for substantial expansion in the coming years, reaching a valuation of $2.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is fueled by several factors, including a rise in biosimilar approvals, the widening presence in emerging markets, the incorporation of AI into drug development processes, a rising demand for outpatient oncology services, and strategic partnerships among pharmaceutical firms. Key trends anticipated during this period encompass a greater acceptance of biosimilars in cancer treatment, the availability of more economical treatment options, an increase in regulatory clearances for biosimilars, the broadening of hospital and retail pharmacy infrastructures, and the proliferation of specialized cancer treatment facilities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Underlying Factors Are Accelerating The Growth Of The Bevacizumab Biosimilars Market?

An increasing number of cancer cases is anticipated to stimulate expansion within the bevacizumab biosimilar market in the future. Cancer incidence denotes the count of new cancer diagnoses within a specific demographic over a defined duration. Bevacizumab, a biologic, works by hindering tumor angiogenesis, leading to reduced tumor size and inhibited growth, and it demonstrates comparable effectiveness and safety to its reference biologics for individuals with advanced non-small cell lung cancer or metastatic colorectal cancer. For example, in October 2025, the NHS England, a UK-based government department, reported 354,820 new cancer diagnoses in England in 2023, representing an increase of 8,605 compared to 2022. Consequently, the growing incidence of cancer cases fuels the bevacizumab biosimilars market.

What Market Segments Are Evaluated Within The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

What Industry Trends Are Redefining The Bevacizumab Biosimilars Market?

Key companies operating within the bevacizumab biosimilars market are concentrating on technological advancements, such as next-generation formulations with broadened indications, to satisfy the increasing demand for more adaptable and economical biologic treatments across both oncology and non-oncology conditions. These advanced formulations modify the core bevacizumab antibody for new delivery methods or uses, enabling non-cancerous applications (like in ophthalmology) or more patient-friendly dosing, while retaining the same VEGF-neutralizing mechanism as traditional intravenous bevacizumab. For instance, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched Versavo (bevacizumab) in the UK. This high-quality biosimilar of Avastin (bevacizumab), designed for oncology uses, makes the treatment costs for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more attainable for a greater number of patients. Versavo is supplied in 100 mg and 400 mg single-use vials, matching standard bevacizumab dosing, and offers a biosimilar cost-benefit that helps alleviate the financial burden on healthcare systems and patients who rely on anti-VEGF therapy.

Who Are The Top Market Participants Influencing The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Read the full bevacizumab biosimilars market report here:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Is Projected To Dominate The Bevacizumab Biosimilars Market During The Forecast Period?

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Bevacizumab Biosimilars Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the bevacizumab biosimilars market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Bevacizumab Biosimilars Market expected to reach by 2030?

The bevacizumab biosimilars market has demonstrated substantial growth in its size over recent years. It is projected to expand from $1.64 billion in 2025 to $1.77 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. The expansion observed historically can be attributed to factors such as the patent expiry of reference bevacizumab, an increase in cancer prevalence, the demand for cost-effective biologics, government incentives for biosimilars, and advancements in recombinant DNA technology.

The market for bevacizumab biosimilars is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period is attributable to several factors, including a rise in biosimilar approvals, market expansion into developing regions, the incorporation of AI into drug development processes, a rising inclination towards outpatient oncology services, and strategic partnerships among pharmaceutical enterprises. Key trends expected during this period encompass a greater uptake of biosimilars within oncology, the availability of economical treatment options, an increase in regulatory approvals for biosimilars, the broadening of hospital and retail pharmacy infrastructures, and the proliferation of specialized cancer care facilities.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Drivers Are Driving Adoption Within The Bevacizumab Biosimilars Market?

An increasing number of cancer cases is anticipated to boost the expansion of the bevacizumab biosimilar market in the future. Cancer incidence is defined as the count of newly identified cancer cases within a particular demographic over a certain timeframe. Bevacizumab, a biologic drug, works by inhibiting the formation of new blood vessels in tumors (angiogenesis), thereby contributing to tumor reduction and hindering its growth. Its effectiveness and safety for patients with advanced non-small cell lung cancer or metastatic colorectal cancer are on par with reference biologics. As an illustration, data from October 2025, provided by NHS England, a UK government body, indicated 354,820 new cancer diagnoses in England during 2023, representing an increase of 8,605 cases compared to 2022. Consequently, the growing incidence of cancer cases fuels the demand for the bevacizumab biosimilars market.

How Is The Bevacizumab Biosimilars Market Organized Into Various Segments?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Which Trends Are Influencing The Performance And Direction Of The Bevacizumab Biosimilars Market?

Major companies in the bevacizumab biosimilars market are concentrating on technological progress, such as advanced indication-expanded formulations, to satisfy the growing demand for more adaptable and affordable biologic therapies across oncology and non-oncology uses. These sophisticated formulations adapt the core bevacizumab antibody for new delivery methods or indications, allowing for non-oncologic application (like in ophthalmology) or more convenient patient dosing, while still utilizing the same VEGF-neutralizing mechanism found in traditional intravenous bevacizumab. For example, in March 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched Versavo (bevacizumab) in the UK. This high-quality biosimilar of Avastin (bevacizumab) is intended for oncology applications, making treatments for metastatic colorectal cancer, lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer, and breast cancer more accessible and affordable for more patients. Versavo is supplied in 100 mg and 400 mg single-use vials, matching standard bevacizumab dosing while providing a biosimilar cost-benefit that aids in reducing the financial burden on healthcare systems and patients relying on anti-VEGF therapy.

Who Are The Major Companies Operating In The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market are Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2025. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Bevacizumab Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2026, By The Business Research Company

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the bevacizumab biosimilars market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Bevacizumab Biosimilars Market Be Worth By 2029, And What CAGR Will It Achieve?

The bevacizumab biosimilars market size has witnessed substantial growth in recent years. It is projected to expand from $1.53 billion in 2024 to $1.64 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.2%. This historical growth can be attributed to several factors, including patent expiry, cost containment measures in healthcare, the increasing incidence of cancer, heightened market competitiveness, improved patient access and affordability, and the growing acceptance of biosimilars.

The bevacizumab biosimilars market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.23 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.9%. Several factors are expected to contribute to this growth during the forecast period, including the increasing need for cancer therapies, proficiency in biosimilar development expertise, strains on healthcare system pressures, the evolving biosimilar regulatory landscape, and the concept of biosimilar interchangeability. Additionally, key trends anticipated within this period encompass collaborations and partnerships, progress in regulatory advancements and approvals, innovation in biosimilar development, strategic approaches to market access, and the management of biosimilar lifecycle management.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

Which Factors Are Driving The Bevacizumab Biosimilars Market Forward?

The escalating occurrence of cancer cases is projected to stimulate the growth of the bevacizumab biosimilar market. Cancer incidence refers to the count of new cancer diagnoses observed in a particular demographic over a specific period. Bevacizumab is a biologic treatment that functions by inhibiting tumor angiogenesis, which can lead to the shrinking and halted growth of tumors, demonstrating comparable efficacy and safety to reference biologics when treating individuals with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, in October 2024, the UK’s National Health Service (NHS) reported 346,217 new cancer diagnoses in 2022, averaging 948 cases each day. This marks a 5% increase when compared to the 329,664 diagnoses from 2021. Furthermore, cancer diagnoses experienced a 7% rise, growing from 167,917 to 180,877 in 2022. Therefore, the increasing prevalence of cancer cases acts as a key driver for the bevacizumab biosimilars market.

Which Segments Form The Key Structure Of The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

What Strategic Shifts And Innovations Are Influencing The Bevacizumab Biosimilars Market?

Product innovation has emerged as a key trend gaining significant traction in the bevacizumab biosimilars market. Major market players are concentrating their efforts on developing new products to strengthen their position. For instance, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, introduced Abevmy (bevacizumab), a biosimilar akin to Roche’s Avastin (bevacizumab). Abevmy has received approval from Health Canada for use across four oncology indications. The product demonstrates efficacy, safety, and quality comparable to the reference biologic, functioning as a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF).

Which Firms Are Making The Biggest Impact In The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Is Expected To Lead The Bevacizumab Biosimilars Market In The Next Few Years?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2025, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Filgrastim Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Bevacizumab Biosimilars Market From 2025 To 2034?

The bevacizumab biosimilars market has experienced robust expansion in recent years. It is anticipated to grow from $1.53 billion in 2024 to $1.64 billion in 2025, at a compound annual growth rate (CAGR) of 7.2%. This historical growth can be attributed to elements such as patent expiry, efforts to contain healthcare costs, a rising incidence of cancer, strong market competitiveness, improved patient access and affordability, and the increasing acceptance of biosimilars.

The bevacizumab biosimilars market size is anticipated to experience substantial expansion over the next few years. It is projected to grow to $2.23 billion in 2029, achieving a compound annual growth rate (CAGR) of 7.9%. This projected growth can be attributed to an increasing demand for cancer therapies, expertise in biosimilar development, pressures within healthcare systems, the regulatory landscape for biosimilars, and biosimilar interchangeability. Prominent trends expected during this forecast period involve collaborations and partnerships, advancements and approvals in regulations, continued biosimilar development and innovation, market access strategies, and the comprehensive management of the biosimilar lifecycle.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Are The Main Drivers Boosting The Bevacizumab Biosimilars Industry’s Expansion?

The growing incidence of cancer is anticipated to fuel the expansion of the bevacizumab biosimilar market in the foreseeable future. Cancer incidence is defined as the total number of new cancer cases identified within a particular population over a specified timeframe. Bevacizumab acts as a biologic that obstructs tumor angiogenesis, which can lead to the shrinking and inhibited growth of tumors. It exhibits comparable effectiveness and safety to existing reference biologics in the management of advanced non-small cell lung cancer or metastatic colorectal cancer patients. For example, in October 2024, the UK’s National Health Service (NHS) documented 346,217 new cancer diagnoses in 2022, which translates to an average of 948 cases daily. This indicates a 5% surge compared to the 329,664 diagnoses recorded in 2021. Moreover, cancer diagnoses experienced a 7% uptick, rising from 167,917 to 180,877 in 2022. Thus, the escalating prevalence of cancer cases is a key driver for the bevacizumab biosimilars market.

What Are The Major Segments Identified In The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

What Long-Term Trends Will Shape The Future Growth Of The Bevacizumab Biosimilars Industry?

Product innovation has become a pivotal and increasingly favored trend within the bevacizumab biosimilars market. Prominent market participants are directing their efforts toward developing inventive products to solidify their presence. For example, in May 2022, Viatris, a US-based pharmaceutical company, and Biocon Biologics, also a US-based pharmaceutical company, introduced Abevmy (bevacizumab), a biosimilar akin to Roche’s Avastin (bevacizumab). Abevmy secured approval from Health Canada for application across four distinct oncology indications. This product delivers similar efficacy, safety, and quality to its reference biologic, given its nature as a synthesized humanized monoclonal antibody (MA) that effectively binds to and neutralizes the biological function of human vascular endothelial growth factor (VEGF).

Which Key Players Are Driving Competition In The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Bevacizumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Browse Through More Reports Similar to the Global Bevacizumab Biosimilars Market 2025, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Filgrastim Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Bevacizumab Biosimilars Market?

The market size for bevacizumab biosimilars has experienced robust growth in the past years. It is predicted to escalate from a value of $1.53 billion in 2024 to reach $1.64 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. Factors such as patent expiry, efforts to control healthcare costs, rising occurrences of cancer, market competitiveness, patient accessibility and affordability, as well as the acceptance of biosimilars, have been influential in shaping growth during the historic period.

In the coming years, the bevacizumab biosimilars market is projected to experience robust growth. The market is anticipated to expand to a worth of “$2.23 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Factors contributing to this growth during the forecast period include increased demand for treatments for cancer, skills in biosimilar development, pressures within the healthcare system, regulatory landscapes for biosimilars, and biosimilar interchangeability. Key trends expected in the forecast period encompass collaborations and partnerships, advancements and approvals in regulations, development and innovation of biosimilars, strategies for market access, and lifecycle management of biosimilars.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

Which Factors Are Steering Growth In The Bevacizumab Biosimilars Market?

The escalating number of cancer cases is anticipated to fuel the expansion of the bevacizumab biosimilar market. The term “cancer incidence” relates to the total new cancer cases identified within a certain population over a specific time frame. Bevacizumab is a biological product that suppresses tumor angiogenesis, potentially leading to tumor reduction and growth deterrence. Its efficacy and safety are akin to those of reference biologic products when used to treat patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For example, in October 2024, the UK’s National Health Service (NHS) announced 346,217 new cancer cases in 2022, equating to an average of 948 cases daily. This is a 5% increase when compared to the 329,664 cases diagnosed in 2021. There was also a 7% increase in cancer diagnoses, rising from 167,917 to 180,877 in 2022. As such, the escalating occurrence of cancer is what drives the market for bevacizumab biosimilars.

How Is The Global Bevacizumab Biosimilars Market Broken Down By Segment?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

Which Trends Are Likely To Redefine Growth Paths In The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market is witnessing a significant trend of product innovation. Market leaders are focusing on the development of innovative products to enhance their market dominance. Viatris and Biocon Biologics, both US-based pharmaceutical firms, exemplified this trend when they introduced a new biosimilar named Abevmy (bevacizumab), mirroring Roche’s Avastin (bevacizumab), in May 2022. Health Canada has approved Abevmy for use in four oncology areas. Like the original biologic, this product guarantees efficacy, safety, and quality, being a synthetically produced humanized monoclonal antibody (MA) that neutralizes the biological activity of the human vascular endothelial growth factor (VEGF).

Which Firms Are Making The Biggest Impact In The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Bevacizumab Biosimilars Market Expected to Be in 2029?

The market size of bevacizumab biosimilars has seen a robust growth in the recent past. It is projected to increase from $1.53 billion in 2024 to $1.64 billion in 2025, representing a compound annual growth rate (CAGR) of 7.2%. The significant growth during the historic period can be credited to factors like patent expiry, efforts to control healthcare costs, rising prevalence of cancer, market competitiveness, patient accessibility, affordability, and the acceptance of biosimilars.

The market size of bevacizumab biosimilars is forecasted to experience significant expansion in the coming years, growing to “$2.23 billion by 2029 at a compound annual growth rate (CAGR) of 7.9%. A number of factors are driving growth during the forecast period including increased cancer treatment demand, skills in biosimilar development, pressures on the healthcare system, the regulatory environment for biosimilars, and biosimilar interchangeability. Key trends predicted during the forecast period encompass collaborative efforts and partnerships, advancements in regulations and approvals, innovation in biosimilar development, strategies for market access, and biosimilar lifecycle management.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Are The Contributors To Demand In The Bevacizumab Biosimilars Market?

The increasing rates of cancer diagnoses are anticipated to fuel the advancement of the bevacizumab biosimilar market in the future. The incidence of cancer pertains to the emergence of new instances of cancer in a certain population within a specific timeframe. Bevacizumab, a biological inhibitor of tumor angiogenesis, can cause tumors to recede and hinder their growth, and is as effective and safe as its reference biologic equivalent in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. As an example, in October 2024, the National Health Service (NHS) in the UK reported 346,217 new cancer diagnoses, averaging 948 cases daily in 2022, representing a 5% growth in comparison to the 329,664 diagnoses in 2021. There was also a 7% elevation in cancer diagnoses, escalating from 167,917 to 180,877 in 2022. Consequently, the escalating prevalence of cancer is a significant driver for the bevacizumab biosimilars market.

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

Which Emerging Trends And Strategic Shifts Are Shaping The Bevacizumab Biosimilars Market?

In the bevacizumab biosimilars market, product innovation is becoming a significant trend. Key players in the market are focusing on developing unique products to solidify their market position. An example of this was seen in May 2022 when Viatris and Biocon Biologics, both US-based pharmaceutical companies, introduced a biosimilar named Abevmy, a bevacizumab biosimilar to Roche’s Avastin. Health Canada has given approval to Abevmy for application in four oncology areas. The product, which is a synthesized humanized monoclonal antibody (MA), effectively binds to and hampers the biologic impact of human vascular endothelial growth factor (VEGF), ensuring that it provides efficacy, safety, and quality equivalent to the reference biologic.

Who Are The Top-Ranked Companies In The Bevacizumab Biosimilars Market Today?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

How Is Bevacizumab Biosimilars Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model